Role of Intervention and Surgery

  • Anselm UebingEmail author
Part of the Congenital Heart Disease in Adolescents and Adults book series (CHDAA)


Heart failure in adult patients with congenital heart disease (CHD) is often the result of long-standing abnormal workload to the subpulmonary and/or systemic ventricle leading to ventricular dysfunction. Interventional catheter procedures and surgery play a central role in the treatment of heart failure in this patient population by attempting to normalise the working conditions of the heart by reducing ventricular pressure or volume overload. When performed in a timely manner, intervention can prevent irreversible ventricular damage. This chapter will give an overview on commonly performed invasive procedures that aim to protect or improve ventricular function and cardiac output. New interventional therapeutic options such as creation of an interatrial communication are also discussed. Catheter-based interventions and surgery are complementary to each other and to medical therapies, and all three are part of a comprehensive therapeutic approach to heart failure treatment in adults with CHD.


Stenting Transcatheter closure Transcatheter valve implantation Surgical treatment Creation of interatrial communication 


  1. 1.
    Kotowycz MA, Therrien J, Ionescu-Ittu R, Owens CG, Pilote L, Martucci G, Tchervenkov C, Marelli AJ. Long-term outcomes after surgical versus transcatheter closure of atrial septal defects in adults. JACC Cardiovasc Interv. 2013;6:497–503.CrossRefPubMedGoogle Scholar
  2. 2.
    Gatzoulis MA, Hechter S, Webb GD, Williams WG. Surgery for partial atrioventricular septal defect in the adult. Ann Thorac Surg. 1999;67:504–10.CrossRefPubMedGoogle Scholar
  3. 3.
    Fischer G, Stieh J, Uebing A, Hoffmann U, Morf G, Kramer HH. Experience with transcatheter closure of secundum atrial septal defects using the Amplatzer septal occluder: a single centre study in 236 consecutive patients. Heart. 2003;89:199–204.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Du ZD, Hijazi ZM, Kleinman CS, Silverman NH, Larntz K, Investigators A. Comparison between transcatheter and surgical closure of secundum atrial septal defect in children and adults: results of a multicenter nonrandomized trial. J Am Coll Cardiol. 2002;39:1836–44.CrossRefGoogle Scholar
  5. 5.
    DiBardino DJ, McElhinney DB, Kaza AK, Mayer JE. Analysis of the US Food and Drug Administration Manufacturer and User Facility Device Experience database for adverse events involving Amplatzer septal occluder devices and comparison with the Society of Thoracic Surgery congenital cardiac surgery database. J Thorac Cardiovasc Surg. 2009;137:1334–41.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Amin Z, Hijazi ZM, Bass JL, Cheatham JP, Hellenbrand WE, Kleinman CS. Erosion of Amplatzer septal occluder device after closure of secundum atrial septal defects: review of registry of complications and recommendations to minimize future risk. Catheter Cardiovasc Interv. 2004;63:496–502.CrossRefPubMedGoogle Scholar
  7. 7.
    Campbell M. Natural history of atrial septal defect. Br Heart J. 1970;32:820–6.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Nyboe C, Karunanithi Z, Nielsen-Kudsk JE, Hjortdal VE. Long-term mortality in patients with atrial septal defect: a nationwide cohort-study. Eur Heart J. 2017.
  9. 9.
    Murphy JG, Gersh BJ, McGoon MD, Mair DD, Porter CJ, Ilstrup DM, McGoon DC, Puga FJ, Kirklin JW, Danielson GK. Long-term outcome after surgical repair of isolated atrial septal defect. Follow-up at 27 to 32 years. N Engl J Med. 1990;323:1645–50.CrossRefPubMedGoogle Scholar
  10. 10.
    Gatzoulis MA, Freeman MA, Siu SC, Webb GD, Harris L. Atrial arrhythmia after surgical closure of atrial septal defects in adults. N Engl J Med. 1999;340:839–46.CrossRefPubMedGoogle Scholar
  11. 11.
    Diller G-P, Dimopoulos K, Okonko D, Li W, Babu-Narayan SV, Broberg CS, Johansson B, Bouzas B, Mullen MJ, Poole-Wilson PA, Francis DP, Gatzoulis MA. Exercise intolerance in adult congenital heart disease: comparative severity, correlates, and prognostic implication. Circulation. 2005;112:828–35.CrossRefPubMedGoogle Scholar
  12. 12.
    Helber U, Baumann R, Seboldt H, Reinhard U, Hoffmeister HM. Atrial septal defect in adults: cardiopulmonary exercise capacity before and 4 months and 10 years after defect closure. J Am Coll Cardiol. 1997;29:1345–50.CrossRefPubMedGoogle Scholar
  13. 13.
    Giardini A, Donti A, Formigari R, Specchia S, Prandstraller D, Bronzetti G, Bonvicini M, Picchio FM. Determinants of cardiopulmonary functional improvement after transcatheter atrial septal defect closure in asymptomatic adults. J Am Coll Cardiol. 2004;43:1886–91.CrossRefPubMedGoogle Scholar
  14. 14.
    Veldtman GR, Razack V, Siu S, El-Hajj H, Walker F, Webb GD, Benson LN, McLaughlin PR. Right ventricular form and function after percutaneous atrial septal defect device closure. J Am Coll Cardiol. 2001;37:2108–13.CrossRefPubMedGoogle Scholar
  15. 15.
    Attenhofer Jost CH, Oechslin E, Seifert B, Maly F, Fatio R, Turina J, Jenni R. Remodelling after surgical repair of atrial septal defects within the oval fossa. Cardiol Young. 2002;12:506–12.CrossRefPubMedGoogle Scholar
  16. 16.
    Uebing A, Fischer G, Bethge M, Scheewe J, Schmiel F, Stieh J, Brossmann J, Kramer HH. Influence of the pulmonary annulus diameter on pulmonary regurgitation and right ventricular pressure load after repair of tetralogy of Fallot. Heart. 2002;88:510–4.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Gatzoulis MA, Till JA, Somerville J, Redington AN. Mechanoelectrical interaction in tetralogy of Fallot. QRS prolongation relates to right ventricular size and predicts malignant ventricular arrhythmias and sudden death. Circulation. 1995;92:231–7.CrossRefPubMedGoogle Scholar
  18. 18.
    Eyskens B, Reybrouck T, Bogaert J, Dymarkowsky S, Daenen W, Dumoulin M, Gewillig M. Homograft insertion for pulmonary regurgitation after repair of tetralogy of fallot improves cardiorespiratory exercise performance. Am J Cardiol. 2000;85:221–5.CrossRefPubMedGoogle Scholar
  19. 19.
    Frigiola A, Redington AN, Cullen S, Vogel M. Pulmonary regurgitation is an important determinant of right ventricular contractile dysfunction in patients with surgically repaired tetralogy of Fallot. Circulation. 2004;110:II153–7.CrossRefPubMedGoogle Scholar
  20. 20.
    Geva T. Repaired tetralogy of Fallot: the roles of cardiovascular magnetic resonance in evaluating pathophysiology and for pulmonary valve replacement decision support. J Cardiovasc Magn Reson. 2011;13:9.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Gaynor SL, Maniar HS, Bloch JB, Steendijk P, Moon MR. Right atrial and ventricular adaptation to chronic right ventricular pressure overload. Circulation. 2005;112:I212–8.PubMedGoogle Scholar
  22. 22.
    Therrien J, Provost Y, Merchant N, Williams W, Colman J, Webb G. Optimal timing for pulmonary valve replacement in adults after tetralogy of Fallot repair. Am J Cardiol. 2005;95:779–82.CrossRefPubMedGoogle Scholar
  23. 23.
    Uebing A, Fischer G, Schlangen J, Apitz C, Steendijk P, Kramer H-H. Can we use the end systolic volume index to monitor intrinsic right ventricular function after repair of tetralogy of Fallot? Int J Cardiol. 2011;147:52–7.CrossRefPubMedGoogle Scholar
  24. 24.
    Heng EL, Gatzoulis MA, Uebing A, Sethia B, Uemura H, Smith GC, Diller G-P, McCarthy KP, Ho SY, Li W, Wright P, Spadotto V, Kilner PJ, Oldershaw P, Pennell DJ, Shore DF, Babu-Narayan SV. Immediate and midterm cardiac remodeling after surgical pulmonary valve replacement in adults with repaired tetralogy of Fallot: a prospective cardiovascular magnetic resonance and clinical study. Circulation. 2017;136:1703–13.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Baumgartner H, Bonhoeffer P, NMS DG, de Haan F, Deanfield JE, Galie N, Gatzoulis MA, Gohlke-Baerwolf C, Kaemmerer H, Kilner P, Meijboom F, BJM M, Oechslin E, Oliver JM, Serraf A, Szatmari A, Thaulow E, Vouhe PR, Walma E. ESC Guidelines for the management of grown-up congenital heart disease (new version 2010). Eur Heart J. 2010;31:2915–57.CrossRefGoogle Scholar
  26. 26.
    Cheung EW-Y, Wong WH-S, Cheung Y-F. Meta-analysis of pulmonary valve replacement after operative repair of tetralogy of Fallot. Am J Cardiol. 2010;106:552–7.CrossRefPubMedGoogle Scholar
  27. 27.
    Babu-Narayan SV, Diller G-P, Gheta RR, Bastin AJ, Karonis T, Li W, Pennell DJ, Uemura H, Sethia B, Gatzoulis MA, Shore DF. Clinical outcomes of surgical pulmonary valve replacement after repair of tetralogy of Fallot and potential prognostic value of preoperative cardiopulmonary exercise testing. Circulation. 2014;129:18–27.CrossRefPubMedGoogle Scholar
  28. 28.
    Ferraz Cavalcanti PE, Sá MPBO, Santos CA, Esmeraldo IM, De Escobar RR, De Menezes AM, De Azevedo OM, De Vasconcelos Silva FP, RFDA L, RDC L. Pulmonary valve replacement after operative repair of Tetralogy of Fallot: meta-analysis and meta-regression of 3,118 patients from 48 studies. J Am Coll Cardiol. 2013;62:2227–43.CrossRefPubMedGoogle Scholar
  29. 29.
    Bonhoeffer P, Boudjemline Y, Saliba Z, Merckx J, Aggoun Y, Bonnet D, Acar P, Le BJ, Sidi D, Kachaner J. Percutaneous replacement of pulmonary valve in a right-ventricle to pulmonary-artery prosthetic conduit with valve dysfunction. Lancet. 2000;356:1403–5.CrossRefPubMedGoogle Scholar
  30. 30.
    Ansari MM, Cardoso R, Garcia D, Sandhu S, Horlick E, Brinster D, Martucci G, Piazza N. Percutaneous pulmonary valve implantation: present status and evolving future. J Am Coll Cardiol. 2015;66:2246–55.CrossRefPubMedGoogle Scholar
  31. 31.
    Khambadkone S, Coats L, Taylor A, Boudjemline Y, Derrick G, Tsang V, Cooper J, Muthurangu V, Hegde SR, Razavi RS, Pellerin D, Deanfield J, Bonhoeffer P. Percutaneous pulmonary valve implantation in humans: results in 59 consecutive patients. Circulation. 2005;112:1189–97.CrossRefPubMedGoogle Scholar
  32. 32.
    Cheatham JP, Hellenbrand WE, Zahn EM, Jones TK, Berman DP, Vincent JA, McElhinney DB. Clinical and hemodynamic outcomes up to 7 years after transcatheter pulmonary valve replacement in the US melody valve investigational device exemption trial. Circulation. 2015;131:1960–70.CrossRefPubMedGoogle Scholar
  33. 33.
    Lurz P, Giardini A, Taylor AM, Nordmeyer J, Muthurangu V, Odendaal D, Mist B, Khambadkone S, Schievano S, Bonhoeffer P, Derrick G. Effect of altering pathologic right ventricular loading conditions by percutaneous pulmonary valve implantation on exercise capacity. Am J Cardiol. 2010;105:721–6.CrossRefPubMedGoogle Scholar
  34. 34.
    Lurz P, Riede FT, Taylor AM, Wagner R, Nordmeyer J, Khambadkone S, Kinzel P, Derrick G, Schuler G, Bonhoeffer P, Giardini A, Daehnert I. Impact of percutaneous pulmonary valve implantation for right ventricular outflow tract dysfunction on exercise recovery kinetics. Int J Cardiol. 2014;177:276–80.CrossRefPubMedGoogle Scholar
  35. 35.
    Nordmeyer J, Lurz P, Khambadkone S, Schievano S, Jones A, McElhinney DB, Taylor AM, Bonhoeffer P. Pre-stenting with a bare metal stent before percutaneous pulmonary valve implantation: acute and 1-year outcomes. Heart. 2011;97:118–23.CrossRefPubMedGoogle Scholar
  36. 36.
    Uebing A, Rigby ML. The problem of infective endocarditis after transcatheter pulmonary valve implantation. Heart. 2015;10:749–51.CrossRefGoogle Scholar
  37. 37.
    Chen CR, Cheng TO, Huang T, Zhou YL, Chen JY, Huang YG, Li HJ. Percutaneous balloon valvuloplasty for pulmonic stenosis in adolescents and adults. N Engl J Med. 1996;335:21–5.CrossRefPubMedGoogle Scholar
  38. 38.
    Zampi JD, Loccoh E, Armstrong AK, Yu S, Lowery R, Rocchini AP, Hirsch-Romano JC. Twenty years of experience with intraoperative pulmonary artery stenting. Catheter Cardiovasc Interv. 2017;90:398–406.CrossRefPubMedGoogle Scholar
  39. 39.
    Brown ML, Dearani JA, Danielson GK, Cetta F, Connolly HM, Warnes CA, Li Z, Hodge DO, Driscoll DJ, Mayo Clinic Congenital Heart Center. The outcomes of operations for 539 patients with Ebstein anomaly. J Thorac Cardiovasc Surg. 2008;135:1120–36. 1136–7CrossRefPubMedGoogle Scholar
  40. 40.
    Danielson GK, Maloney JD, Devloo RA. Surgical repair of Ebstein’s anomaly. Mayo Clin Proc. 1979;54:185–92.PubMedGoogle Scholar
  41. 41.
    Carpentier A, Chauvaud S, Macé L, Relland J, Mihaileanu S, Marino JP, Abry B, Guibourt P. A new reconstructive operation for Ebstein’s anomaly of the tricuspid valve. J Thorac Cardiovasc Surg. 1988;96:92–101.PubMedGoogle Scholar
  42. 42.
    da Silva JP, Baumgratz JF, da Fonseca L, Franchi SM, Lopes LM, Tavares GMP, Soares AM, Moreira LF, Barbero-Marcial M. The cone reconstruction of the tricuspid valve in Ebstein’s anomaly. The operation: early and midterm results. J Thorac Cardiovasc Surg. 2007;133:215–23.CrossRefPubMedGoogle Scholar
  43. 43.
    Dearani JA, Mora BN, Nelson TJ, Haile DT, O’Leary PW. Ebstein anomaly review: what’s now, what’s next? Expert Rev Cardiovasc Ther. 2015;13:1101–9.CrossRefPubMedGoogle Scholar
  44. 44.
    Brown ML, Dearani JA, Danielson GK, Cetta F, Connolly HM, Warnes CA, Li Z, Hodge DO, Driscoll DJ. Functional status after operation for Ebstein anomaly: the Mayo Clinic experience. J Am Coll Cardiol. 2008;52:460–6.CrossRefPubMedGoogle Scholar
  45. 45.
    Roberts PA, Boudjemline Y, Cheatham JP, Eicken A, Ewert P, McElhinney DB, Hill SL, Berger F, Khan D, Schranz D, Hess J, Ezekowitz MD, Celermajer D, Zahn E. Percutaneous tricuspid valve replacement in congenital and acquired heart disease. J Am Coll Cardiol. 2011;58:118–22.Google Scholar
  46. 46.
    Karonis T, Scognamiglio G, Babu-Narayan SV, Montanaro C, Uebing A, Diller GP, Alonso-Gonzalez R, Swan L, Dimopoulos K, Gatzoulis MA, Li W. Clinical course and potential complications of small ventricular septal defects in adulthood: Late development of left ventricular dysfunction justifies lifelong care. Int J Cardiol. 2016;208:102–6.CrossRefPubMedGoogle Scholar
  47. 47.
    Carminati M, Butera G, Chessa M, Giovanni J De, Fisher G, Gewillig M, Peuster M, Piechaud JF, Santoro G, Sievert H, Spadoni I, Walsh K, Investigators of the European VSD Registry A, Lillehei C, Cohen M, Warden H, Varco R, Kouchoukos N, Blackstone E, Doty D, Hanley F, Karp R, Ross-Hesselink J, Mejiboom F, Spitaels S, Domberg R Van, Rijen E Van, Utens E, Bogers A, Simons M, et al. Transcatheter closure of congenital ventricular septal defects: results of the European Registry. Eur Heart J 2007;28:2361–8.Google Scholar
  48. 48.
    Liddy S, Oslizlok P, Walsh KP. Comparison of the results of transcatheter closure of patent ductus arteriosus with newer Amplatzer devices. Catheter Cardiovasc Interv. 2013;82:253–9.CrossRefPubMedGoogle Scholar
  49. 49.
    Campbell M. Natural history of coarctation of the aorta. Br Heart J. 1970;32:633–40.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Torok RD, Campbell MJ, Fleming GA, Hill KD. Coarctation of the aorta: Management from infancy to adulthood. World J Cardiol. 2015;7:765–75.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Massey R, Shore DF. Surgery for complex coarctation of the aorta. Int J Cardiol. 2004;97:67–73.CrossRefPubMedGoogle Scholar
  52. 52.
    Forbes TJ, Kim DW, Du W, Turner DR, Holzer R, Amin Z, Hijazi Z, Ghasemi A, Rome JJ, Nykanen D, Zahn E, Cowley C, Hoyer M, Waight D, Gruenstein D, Javois A, Foerster S, Kreutzer J, Sullivan N, Khan A, Owada C, Hagler D, Lim S, Canter J, Zellers T, CCISC Investigators. Comparison of surgical, stent, and balloon angioplasty treatment of native coarctation of the aorta: an observational study by the CCISC (Congenital Cardiovascular Interventional Study Consortium). J Am Coll Cardiol. 2011;58:2664–74.CrossRefGoogle Scholar
  53. 53.
    Forbes TJ, Garekar S, Amin Z, Zahn EM, Nykanen D, Moore P, Qureshi SA, Cheatham JP, Ebeid MR, Hijazi ZM, Sandhu S, Hagler DJ, Sievert H, Fagan TE, Ringewald J, Du W, Tang L, Wax DF, Rhodes J, Johnston TA, Jones TK, Turner DR, CAC P, Hellenbrand WE, Congenital Cardiovascular Interventional Study Consortium (CCISC). Procedural results and acute complications in stenting native and recurrent coarctation of the aorta in patients over 4 years of age: a multi-institutional study. Catheter Cardiovasc Interv. 2007;70:276–85.CrossRefPubMedGoogle Scholar
  54. 54.
    Fawzy ME, Sivanandam V, Pieters F, Stefadouros MA, Galal O, Dunn B, Kinsara A, Khan B, Al-Halees Z. Long-term effects of balloon angioplasty on systemic hypertension in adolescent and adult patients with coarctation of the aorta. Eur Heart J. 1999;20:827–32.CrossRefPubMedGoogle Scholar
  55. 55.
    Lam Y-Y, Kaya MG, Li W, Mahadevan VS, Khan AA, Henein MY, Mullen M. Effect of endovascular stenting of aortic coarctation on biventricular function in adults. Heart. 2007;93:1441–7.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Hassan W, Awad M, Fawzy ME, Al OA, Malik S, Akhras N, Shoukri M. Long-term effects of balloon angioplasty on left ventricular hypertrophy in adolescent and adult patients with native coarctation of the aorta. Up to 18 years follow-up results. Catheter Cardiovasc Interv. 2007;70:881–6.CrossRefPubMedGoogle Scholar
  57. 57.
    Diller G-P, Kempny A, Alonso-Gonzalez R, Swan L, Uebing A, Li W, Babu-Narayan S, Wort SJ, Dimopoulos K, Gatzoulis MA. Survival prospects and circumstances of death in contemporary adult congenital heart disease patients under follow-up at a large tertiary centre. Circulation. 2015;132:2118–25.CrossRefPubMedGoogle Scholar
  58. 58.
    Kreutzer J, Graziano JN, Stapleton G, Rome JJ. Late catheter interventions in hypoplastic left heart syndrome. Cardiol Young. 2011;21(Suppl 2):65–76.CrossRefPubMedGoogle Scholar
  59. 59.
    Hansen JH, Runge U, Uebing A, Scheewe J, Kramer H-H, Fischer G. Cardiac catheterization and interventional procedures as part of staged surgical palliation for hypoplastic left heart syndrome. Congenit Heart Dis. 2012;7:565–74.CrossRefPubMedGoogle Scholar
  60. 60.
    Sagic D, Otasevic P, Sievert H, Elsasser A, Mitrovic V, Gradinac S. Percutaneous implantation of the left ventricular partitioning device for chronic heart failure: a pilot study with 1-year follow-up. Eur J Heart Fail. 2010;12:600–6.CrossRefPubMedGoogle Scholar
  61. 61.
    Søndergaard L, Reddy V, Kaye D, Malek F, Walton A, Mates M, Franzen O, Neuzil P, Ihlemann N, Gustafsson F. Transcatheter treatment of heart failure with preserved or mildly reduced ejection fraction using a novel interatrial implant to lower left atrial pressure. Eur J Heart Fail. 2014;16:796–801.CrossRefPubMedGoogle Scholar
  62. 62.
    Hasenfuß G, Hayward C, Burkhoff D, Silvestry FE, McKenzie S, Gustafsson F, Malek F, Van der HJ, Lang I, Petrie MC, Cleland JGF, Leon M, Kaye DM. A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE LAP-HF): a multicentre, open-label, single-arm, phase 1 trial. Lancet. 2016;387:1298–304.CrossRefPubMedGoogle Scholar
  63. 63.
    Tutarel O, Kempny A, Alonso-Gonzalez R, Jabbour R, Li W, Uebing A, Dimopoulos K, Swan L, Gatzoulis MA, Diller GP. Congenital heart disease beyond the age of 60: emergence of a new population with high resource utilization, high morbidity, and high mortality. Eur Heart J. 2014;35:725–32.CrossRefPubMedGoogle Scholar
  64. 64.
    Taramasso M, Hahn RT, Alessandrini H, Latib A, Attinger-Toller A, Braun D, Brochet E, Connelly KA, Denti P, Deuschl F, Englmaier A, Fam N, Frerker C, Hausleiter J, Juliard J-M, Kaple R, Kreidel F, Kuck KH, Kuwata S, Ancona M, Malasa M, Nazif T, Nickenig G, Nietlispach F, Pozzoli A, Schäfer U, Schofer J, Schueler R, Tang G, Vahanian A, et al. The International Multicenter TriValve Registry: which patients are undergoing transcatheter tricuspid repair? JACC Cardiovasc Interv. 2017;10:1982–90.CrossRefPubMedGoogle Scholar
  65. 65.
    Franzen O, von Samson P, Dodge-Khatami A, Geffert G, Baldus S. Percutaneous edge-to-edge repair of tricuspid regurgitation in congenitally corrected transposition of the great arteries. Congenit Heart Dis. 2011;6:57–9.CrossRefPubMedGoogle Scholar
  66. 66.
    Stephan von Bardeleben R, Tamm A, Emrich T, Münzel T, Schulz E. Percutaneous transvenous direct annuloplasty of a human tricuspid valve using the Valtech Cardioband. Eur Heart J. 2017;38:690.CrossRefPubMedGoogle Scholar
  67. 67.
    Duncan A, Daqa A, Yeh J, Davies S, Uebing A, Quarto C, Moat N. Transcatheter mitral valve replacement: long-term outcomes of first-in-man experience with an apically tethered device—a case series from a single centre. EuroIntervention. 2017;13:e1047–57.CrossRefPubMedGoogle Scholar
  68. 68.
    Lauten A, Laube A, Schubert H, Bischoff S, Nietzsche S, Horstkötter K, Poudel-Bochmann B, Franz M, Lichtenberg A, Figulla HR, Akhyari P. Transcatheter treatment of tricuspid regurgitation by caval valve implantation—experimental evaluation of decellularized tissue valves in central venous position. Catheter Cardiovasc Interv. 2015;85:150–60.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Paediatric CardiologyUniversity Hospital MünsterMünsterGermany

Personalised recommendations